<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39465816</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>41</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Unveiling the significance of Gremlin-1 as a novel biomarker for enhanced severity prediction in COVID-19 patients.</ArticleTitle><Pagination><StartPage>e40001</StartPage><MedlinePgn>e40001</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e40001</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000040001</ELocationID><Abstract><AbstractText>Gremlin-1 is associated with lung disease and plays a role in the initiation and progression of pulmonary fibrosis. This suggests that Gremlin-1 may be associated with lung involvement in COVID-19 and poor clinical outcomes and warrants further investigation. This prospective, cross-sectional, single-blind study was the first to investigate Gremlin-1 levels in COVID-19 patients and whether Gremlin-1 levels could be used to predict and guide clinical follow-up in outpatients and inpatients. In this context, serum Gremlin-1 levels were measured and compared in 2 groups of patients who were diagnosed as positive for COVID-19 by RT-PCR and were followed up as outpatients (n = 28) or required hospitalization (n = 30). The median Gremlin-1 values were statistically significantly different between outpatients and intensive care unit patients (0.367 ng/mL [IQR = 0.377], 1.858 ng/mL [IQR = 2.245], respectively) (P &lt; .0001). The area under the ROC curve value to determine the discriminative power of Gremlin-1 was found to be 0.772 (95% CI: 0.672-0.871; P &lt; .0001), and the cutoff value of Gremlin-1 to discriminate between outpatients and hospitalized patients was found to be 1.242 ng/mL with 66.7% sensitivity and 67.2% specificity. Serum Gremlin-1 level is an important biomarker that can be used as a clinical decision-making tool for COVID-19 positive patients.</AbstractText><CopyrightInformation>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Celik</LastName><ForeName>Muhammet</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9536-8101</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Faculty of Medicine, Ataturk University, Erzurum, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tekin</LastName><ForeName>Erdal</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6158-0286</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, Ataturk University, Medical Faculty, Erzurum, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koçak</LastName><ForeName>Mehmet Nuri</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ataturk University Medical Faculty, Erzurum, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uzunçakmak</LastName><ForeName>Sevgi Karabulut</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Health Services, Bayburt University Vocational School, Bayburt, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayraktar</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Ataturk University, Medical Faculty, Erzurum, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486399">GREM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036341">Intercellular Signaling Peptides and Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036341" MajorTopicYN="Y">Intercellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>8</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39465816</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000040001</ArticleId><ArticleId IdType="pii">00005792-202410110-00034</ArticleId><ArticleId IdType="pmc">PMC11479505</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard.
Available at: https://covid19.who.int/. Accessed November 05, 2023.</Citation></Reference><Reference><Citation>Mehta P, Fajgenbaum DC. Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. Curr Opin Rheumatol. 2021;33:419–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373392</ArticleId><ArticleId IdType="pubmed">34264880</ArticleId></ArticleIdList></Reference><Reference><Citation>Broman N, Rantasärkkä K, Feuth T, et al. . IL-6 and other biomarkers as predictors of severity in COVID-19. Ann Med. 2021;53:410–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7935117</ArticleId><ArticleId IdType="pubmed">33305624</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglini D, Lopes-Pacheco M, Castro-Faria-Neto HC, Pelosi P, Rocco PRM. Laboratory biomarkers for diagnosis and prognosis in COVID-19. Front Immunol. 2022;13:857573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9091347</ArticleId><ArticleId IdType="pubmed">35572561</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillo E, Ravelli C, Colleluori G, et al. . Role of Gremlin-1 in the pathophysiology of the adipose tissues. Cytokine Growth Factor Rev. 2023;69:51–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">36155165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciuclan L, Sheppard K, Dong L, et al. . Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice. Am J Pathol. 2013;183:1461–73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5691347</ArticleId><ArticleId IdType="pubmed">24160323</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoshima Y, Enomoto Y, Muto S, et al. . Gremlin-1 for the differential diagnosis of idiopathic pulmonary fibrosis versus other interstitial lung diseases: a clinical and pathophysiological analysis. Lung. 2021;199:289–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8203516</ArticleId><ArticleId IdType="pubmed">33770226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahill E, Costello CM, Rowan SC, et al. . Gremlin plays a key role in the pathogenesis of pulmonary hypertension. Circulation. 2012;125:920–30.</Citation><ArticleIdList><ArticleId IdType="pubmed">22247494</ArticleId></ArticleIdList></Reference><Reference><Citation>The Ministry of Health of Turkey. COVID-19 informational platform. General coronavirus chart.
https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html. Accessed August 30, 2024.</Citation></Reference><Reference><Citation>Turkish Thorax Society. COVID-19 task group opinion report. In: Köktürk N, İtil O, eds. Turkish; 2020:31–2. https://toraks.org.tr/site/sf/documents/2024/01/bc1b9db5b7f1b13c5d839c3d4a8d2a7ef78bd70cebf9cd0101482982c26d6af3.pdf#page=16. Accessed August 30, 2024.</Citation></Reference><Reference><Citation>Müller II, Chatterjee M, Schneider M, et al. . Gremlin-1 inhibits macrophage migration inhibitory factor-dependent monocyte function and survival. Int J Cardiol. 2014;176:923–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25194861</ArticleId></ArticleIdList></Reference><Reference><Citation>Du XF, Huang K, Chen XY, et al. . Gremlin-1 promotes IL-1β-stimulated chondrocyte inflammation and extracellular matrix degradation via activation of the MAPK signaling pathway. J Biochem Mol Toxicol. 2023;37:e23404.</Citation><ArticleIdList><ArticleId IdType="pubmed">37352019</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao YD, Ding M, Dong X, et al. . Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76:428–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">33185910</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee M, Behrendt A, Schmid M, et al. . Platelets as a novel source of Gremlin-1: Implications for thromboinflammation. Thromb Haemost. 2017;117:311–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">27929199</ArticleId></ArticleIdList></Reference><Reference><Citation>Gris JC, Perez-Martin A, Quéré I, Sotto A. COVID-19 associated coagulopathy: the crowning glory of thrombo-inflammation concept. Anaesth Crit Care Pain Med. 2020;39:381–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196534</ArticleId><ArticleId IdType="pubmed">32418867</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Reilly S. Gremlin: a complex molecule regulating wound healing and fibrosis. Cell Mol Life Sci. 2021;78:7917–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11071963</ArticleId><ArticleId IdType="pubmed">34731251</ArticleId></ArticleIdList></Reference><Reference><Citation>Crudele L, Novielli F, Petruzzelli S, et al. . Liver fibrosis indices predict the severity of SARS-CoV-2 infection. J Clin Med. 2022;11:5369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9500647</ArticleId><ArticleId IdType="pubmed">36143014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>